Enterprise record

AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:b92e141d-3c35-4f76-afa0-2d12534e9412Version: public-1As of: unavailable

19 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 28, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026

    Supports 3 claims
    • Legal Name: AN2 Therapeutics, Inc. · Claim reviewed: Sep 28, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
    • Published Fact: US · Claim reviewed: Sep 28, 2026

  2. SEC DEF 14A 0001193125-26-170314

    sec def 14a · Source published: Apr 22, 2026 · Retrieved: Sep 5, 2026

    Supports 12 claims
    • Leadership Role: Eric Easom: President, Chief Executive Officer and Board Chair · Claim reviewed: Sep 28, 2026
    • Leadership Role: Gilbert Lynn Marks, M.D.: Class I Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Joseph Zakrzewski: Class III Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Kabeer Aziz: Class I Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Margaret FitzPatrick: Class II Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Melvin Spigelman, M.D.: Class II Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Patricia Martin: Class II Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Rob Readnour, Ph.D.: Class I Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Stephanie Wong: Class III Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Eric Easom: President, Chief Executive Officer and Board Chair · Claim reviewed: Sep 28, 2026
    • Leadership Role: Lucy Day: Chief Financial Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Sanjay Chanda, Ph.D.: Chief Development Officer · Claim reviewed: Sep 28, 2026

  3. DEF 14A antx-20260422.htm

    sec proxy · Source published: Apr 22, 2026 · Retrieved: Sep 2, 2026

    Supports 4 claims
    • Leadership Role: Gilbert Lynn Marks: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Melvin Spigelman: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Rob Readnour: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Joshua Eizen: Chief Legal Officer and Chief Operating Officer · Claim reviewed: Sep 28, 2026